August 29, 2021
With the MDR, the clinical investigations (see Chapter VI, Art. 61-82 and Annex XV) must establish compliance with the performance and safety requirements, in particular
Clinical investigation is designed to ensure the protection of the rights, safety, dignity and well-being of individuals, the scientific validity, reliability and robustness of clinical data.
In general, the DM undergoing clinical investigation complies with the general safety and performance requirements set out in Annex I (with the obvious exception of evidence requiring clinical investigation)and the requirements of Annex XV (general requirements, documentation of the clinical investigation application, other obligations of the sponsor in Chapter III).
All these guarantees are ensured by scientific and/or ethical review by the competent authorities.
Clinical investigations are an integral part of the broader concept of "clinical evaluation" and are mandatory for implantable medical devices (IMDs) and Class III devices (with clearly established exceptions, see Entry into force of Regulation 2017/245 on medical devices: update on clinical evaluation).
For any clinical investigation conducted at at least 1 investigator site in the EU, the sponsor or its legal representative must be established in the EU.
To date, the evaluation procedure remains purely national and is therefore the responsibility of a designated French Ethical Commitee, i.e. Comité de Protection des Personnes (CPP), and the ANSM.
In the future, for clinical investigations conducted in several Member States, the evaluation procedure will be coordinated by a coordinating Member State, but the ethical review will remain national and will therefore always be the responsibility of a CPP on French territory. This procedure will be mandatory from 26 May 2027.
Before that date, the possibility of using this procedure will depend on the establishment of the EUDAMED database, which will be the entry point for any notification or request for a clinical investigation, regardless of the procedure, and will be accompanied by the documentation referred to inAnnex XV.
The commencement of the clinical investigation is subject to coordinated validation by the ANSM and must therefore fall within the scope of the MDR (device, class, CE marking or post-marketing clinical follow-up(PMCS)) and be the subject of a complete dossier (see Annex XV).
Following validation, clinical investigations can only be implemented after a favourable opinion (even if the MDR uses the notion of no unfavourable opinion) issued by the designated CPP, and if necessary after authorisation by the ANSM.
It should be noted that several evaluation procedures and timeframes coexist depending on the type of clinical investigation envisaged: with or without CE marking, use within or outside the intended purpose, presence or absence of invasiveprocedures and class of the device.
In any case, SCAC procedures without additional procedures will not be considered clinical investigations but routine care outside the scope of clinical investigations.
Clinical investigations continuing beyond 26 May 2021 will continue to be governed under the national provisions of the Jardé Law (Articles L. 1121-1 and seq. and R. 1121-1 et seq. of the Public Health Code), except for the vigilance of such research, which will henceforth be governed by the provisions of the MDR.
The deadlines for vigilance reporting are as follows:
- from the investigator to the sponsor:
- from the sponsor to the ANSM :
Since June 10, 2023, influencer activity has been subject to its own regulations. Here's a look at its impact on healthcare.
Medical device law
A look back at the CNOCD's report on the state of its anti-gift law enforcement practices